Relationship between esomeprazole dose and timing to heartburn resolution in selected patients with gastroesophageal reflux disease

Clinical and Experimental Gastroenterology

Volumn 3, Issue 1, 2010, Pages 117-125

  Orlando, Roy C ^a   Liu, Sherry ^b   Illueca, Marta ^c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Department of Statistics and Informatics ^*  (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Acid suppressive therapy; GERD; Proton pump inhibitor

Indexed keywords

ATTAPULGITE; ESOMEPRAZOLE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS PH; FATIGUE; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; HYPERHIDROSIS; INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; THORAX PAIN; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 77957156554     PISSN: None     EISSN: 11787023     Source Type: Book Series    
DOI: 10.2147/CEG.S12333     Document Type: Article

References (39)

1. Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro- oesophageal reflux disease: A systematic review. Gut. 2005;54: 710-717.
2. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut. 1999;44 Suppl 2: S1-S16.
3. deVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005; 100:190-200.
4. Numans ME, Lau J, de Wit NJ, et al. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease. A meta-analysis of diagnostic test characteristics. Ann Intern Med. 2004;140:518-527.
5. Bernstein LM, Fruin RD, Pacini R. Differentiation of esophageal pain from angina pectoris: Role of the esophageal acid perfusion test. Medicine (Baltimore). 1962;41:143-162.
6. Richter JE. Acid perfusion (Bernstein) test. In: Castell DO, Wu WC, Ott DJ, editors. Gastroesophageal Reflux Disease: Pathogenesis, Diagnosis, Therapy. Mount Kisco, NY: Futura Publishing Co. Inc.; 1985.
7. Howard PJ, Maher L, Pryde A, et al. Symptomatic gastro-oesophageal reflux, abnormal oesophageal acid exposure, and mucosal acid sensitivity are three separate, though related, aspects of gastro-oesophageal reflux disease. Gut. 1991;32:128-132.
8. Jung B, Steinbach J, Beaumont C, et al. Lack of association between esophageal acid sensitivity detected by prolonged pH monitoring and Bernstein testing. Am J Gastroenterol. 2004;99:410-415.
9. American Gastroenterological Association (AGA) Institute Medical Position Panel. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1383-1391.
10. Fass R, Shapiro M, Dekel R, et al. Systematic review: Proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther. 2005;22:79-94.
11. Bell NJV, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992;51 Suppl 1:59-67.
12. Spechler SJ, Sharma P, Traxler B, et al. Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: A randomized, double-blind, crossover trial. Am J Gastroenterol. 2006;101:1964-1971.
13. Hammer J, Schmidt B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment Pharmacol Ther. 2004;19:1105-1110.
14. Katz PO, Castell DO, Chen Y, et al. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: A randomized, threeway crossover study. Aliment Pharmacol Ther. 2004;20:399-406.
15. Hatlebakk JG, Katz PO, Kuo B, et al. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther. 1998;12:1235-1240.
16. Pehlivanov ND, Olyaee M, Sarosiek I, et al. Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: A double-blind, cross-over study. Aliment Pharmacol Ther. 2003;18:883-890.
17. Röhss K, Wilder-Smith C, Sagar M, et al. Can acid control be improved with a modified-release formulation of a proton pump inhibitor? [Abstr 48]. Am J Gastroenterol. 2008;103 Suppl 1:S19.
18. Röhss K, Wilder-Smith C, Sagar M, et al. Dose and timing effects of esomeprazole administration on 24-h intragastric pH control [Abstr 60]. Am J Gastroenterol. 2008;103 Suppl 1:S24.
19. Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656-664.
20. Martinez SD, Malagon IB, Garewal HS, et al. Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17:537-545.
21. Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006;367:2086-2100.
22. World Medical Association. Ethical Principles for Medical Research Involving Human Subjects. Presented at: 59th WMA General Assembly, Seoul, Oct 2008. Available from: http://www.wma.net. Accessed Nov 12, 2008.
23. European Medicines Agency. ICH Topic E 6 (R1): Guidelines for Good Clinical Practice. European Agency for the Evaluation of Medicinal Products. Updated 2006. Available from: http://www.emea.eu/pdfs/ human/ich/013595en.pdf. Accessed May 13, 2009.
24. Katz PO, Castell DO, Levine D. Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther. 2003;18:875-882.
25. Armstrong D, Talley NJ, Lauritsen K, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: The effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther. 2004;20:413-421.
26. Puhan MA, Guyatt GH, Armstrong D, et al. Validation of a symptom diary for patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;23:531-541.
27. Wiener GJ, Richter JE, Copper JB, et al. The symptom index: A clinically important parameter of ambulatory 24-hour esophageal pH monitoring. Am J Gastroenterol. 1988;83:358-361.
28. Calabrese C, Fabbri A, Bortolotti M, et al. Dilated intercellular spaces as a marker of oesophageal damage: Comparative results in gastrooesophageal reflux disease with or without bile reflux. Aliment Pharmacol Ther. 2003;18:525-532.
29. Calabrese C, Bortolotti M, Fabbri A, et al. Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. Am J Gastroenterol. 2005;100:537-542.
30. Shaker R, Castell DO, Schoenfeld PS, et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: The results of a Gallup Survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 2003;98:1487-1493.
31. Orr WC, Goodrich S, Robert J. The effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal reflux. Aliment Pharmacol Ther. 2005;21:103-108.
32. Yi CH, Chen CL, Kuo TBJ, et al. The effect of acid suppression on sleep and cardiac autonomic regulation in GERD. Hepatogastroenterology. 2008;55:1649-1652.
33. Johnson DA, Crawley JA, Hwang C, et al. Effect of esomeprazole on sleep quality in patients with gastroesophageal reflux disease (GERD)-related sleep disturbances [Abstr]. Gastroenterology. 2009;136 Suppl 1:417.
34. Johnson DA, Orr WC, Crawley JA, et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: A randomized, placebo-controlled trial. Am J Gastroenterol. 2005;100:1914-1922.
35. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro- oesophageal reflux disease: A double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther. 1997;11: 765-773.
36. Miner P Jr, Orr W, Filippone J, et al. Rabeprazole in nonerosive gastroesophageal reflux disease: A randomized placebo-controlled trial. Am J Gastroenterol. 2002;97:1332-1339.
37. Richter JE, Kovacs TOG, Greski-Rose PA, et al. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther. 1999;13:795-804.
38. Kahrilas PJ, Falk GW, Johnson DA, et al; for the Esomeprazole Study Investigators. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial. Aliment Pharmacol Ther. 2000;14: 1249-1258.
39. Katz PO, Ginsberg GG, Hoyle PE, et al. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther. 2007;25:617-628.